In this week’s edition of InnovationRx, we explore the impact of Hinge Health’s successful IPO, Kiran Mazumdar-Shaw’s ‘biosimilars’ business, RFK’s changes to Covid vaccine guidance, and more. To receive it in your inbox, subscribe here.
Lex Annison, COO of Hinge Health, Gabriel Mecklenburg, executive chairman, Daniel Perez, CEO, Bianca Buck, head of investor relations, James Budge, CFO, and Jim Pursley, president, ring a ceremonial bell on the floor of the New York Stock Exchange during the company’s IPO.
© 2025 Bloomberg Finance LP
Digital physical therapy company Hinge Health made its debut on the stock market last week, starting at $37.85. It is currently trading over 10% above that price, with a market cap exceeding $3.2 billion. The company offers personalized care plans for individuals with chronic conditions, along with software that facilitates coordination with healthcare providers.
Another player in the virtual chronic care space, Omada Health, also filed for an IPO earlier this month. The success of Hinge Health’s IPO could signal a new wave of digital health companies seeking public listings post-COVID-19, according to Pitchbook analyst Aaron DeGagne.
Meet India’s Self-Made Biologics Brewmaster Billionaire
Kiran Mazumdar
Guerin Blask for Forbes
Kiran Mazumdar-Shaw’s thriving drug business had humble beginnings in a tin-roofed shed in Bengaluru, where she initially focused on fermenting enzymes for industrial use. Fast forward to today, and Biocon, the company she co-founded, generates $1.9 billion in revenue through the sale of generic drugs and biosimilar medications.
Mazumdar-Shaw’s wealth and success have positioned her as one of the world’s wealthiest self-made female entrepreneurs, with an estimated fortune of $3.2 billion. Her company’s subsidiary, Biocon Biologics, is a key player in the biosimilars market, offering affordable alternatives to biologic drugs.
Read more about Mazumdar-Shaw’s journey here.
BIOTECH AND PHARMA
GSK and Spero Therapeutics announced positive results from their phase 3 trial of tebipenem HBr, an antibiotic for UTIs, outperforming the current standard of care. The study’s success led to an early halt and plans for FDA submission later this year.
Additionally, Gilgamesh Pharmaceuticals released promising data on their drug candidate GM-2505 for patients with major depression.
DIGITAL HEALTH AND AI
Abhinav Shashank, CEO of Innovaccer, identified a common challenge in healthcare technology integration and introduced Gravity, a comprehensive software platform aimed at streamlining data management and tool utilization for large healthcare systems. Learn more here.
Moreover, Ambience Healthcare’s AI models have shown a significant reduction in medical coding errors by over 25% compared to manual coding.
PUBLIC HEALTH AND HOSPITALS
HHS Secretary Robert F. Kennedy, Jr. announced changes in CDC recommendations regarding Covid vaccines for pregnant women and healthy children, sparking debate among experts. The FDA’s stance on vaccinating individuals under 65, including pregnant women, appears to conflict with the CDC’s revised guidance.
WHAT WE’RE READING
RFK Jr. delves into the first MAHA commission report on children’s health.
Biotech companies face challenges due to expensive leases, particularly in industry hubs like Boston, San Francisco, and San Diego.
Eli Lilly’s acquisition of SiteOne Therapeutics, a company developing non-opioid pain medication, is valued at up to $1 billion.
Neuralink secures $600 million in funding, valuing the company at $9 billion, as it continues to advance brain-computer interface technology.
Measles cases decline in Texas but rise in states like Iowa, which reported its first infection since 2019.
Conservative groups advocate for stricter regulations around in vitro fertilization in discussions with the Trump Administration.
MORE FROM FORBES
